Medicenna, a clinical stage immunotherapy company, is focusing on developing new versions of IL-2, IL-4, and IL-13 Superkines, and Empowered Cytokines™ (ECs) for cancer treatment. The company's lead IL4-EC, MDNA55, has completed a Phase 2b clinical trial for the treatment of rGBM, the most fatal form of brain cancer. It has demonstrated significant efficacy and obtained Fast-Track and Orphan Drug status. Medicenna's potential long-acting IL2 Superkine, MDNA11, is expected to be a best-in-class next-generation IL-2, with superior binding and a preference for cancer-killing effector T cells and NK cells. The drug is set to be ready for clinical trials in 2021.